BioSpace News Archive

Nineteen percent of COVID-19 patients without symptoms went on to exhibit at least one of the post-COVID conditions known as long-haul COVID 30 days or more after their initial COVID-19 diagnosis.1 This is among the findings in FAIR Health’s new white paper, the eighth of its COVID-19 studies, A Detailed Study of Patients with Long-Haul COVID: An Analysis of Private Healthcare Claims.

PulmoSIM Therapeutics (PulmoSIM), the pharmaceutical subsidiary of VeriSIM Life, Inc., is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for asset PT001 for the treatment of Pulmonary Arterial Hypertension (PAH).